Targeting Cathepsin E in Pancreatic Cancer by a Small Molecule Allows In Vivo Detection  by Keliher, Edmund J. et al.
Targeting Cathepsin E
in Pancreatic Cancer by
a Small Molecule Allows
In Vivo Detection1,2
Edmund J. Keliher*,3, Thomas Reiner*,†,3,
Sarah Earley*, Jenna Klubnick*, Carlos Tassa*,
Andrew J. Lee‡, Sridhar Ramaswamy‡,
Nabeel Bardeesy‡, Douglas Hanahan§,
Ronald A. DePinho¶, Cesar M. Castro*,‡
and Ralph Weissleder*,‡,#
*Center for Systems Biology, Massachusetts General
Hospital, Boston, MA; †Department of Radiology,
Memorial Sloan-Kettering Cancer Center, New York,
NY; ‡Massachusetts General Hospital Cancer Center,
Harvard Medical School, Boston, MA; §Swiss Institute for
Experimental Cancer Research, Lausanne, Switzerland;
¶MD Anderson Cancer Center, Houston, TX; #Department
of Systems Biology, Harvard Medical School, Boston, MA
Abstract
When resectable, invasive pancreatic ductal adenocarcinoma (PDAC) is most commonly treated with surgery and
radiochemotherapy. Given the intricate local anatomy and locoregional mode of dissemination, achieving clean sur-
gical margins can be a significant challenge. On the basis of observations that cathepsin E (CTSE) is overexpressed
in PDAC and that an United States Food and Drug Administration (FDA)-approved protease inhibitor has high affinity
for CTSE, we have developed a CTSE optical imaging agent [ritonavir tetramethyl-BODIPY (RIT-TMB)] for potential
intraoperative use. We show nanomolar affinity [half maximal inhibitory concentration (IC50) of 39.9 ± 1.2 nM] against
CTSE of the RIT-TMB in biochemical assays and intracellular accumulation and target-to-background ratios that
allow specific delineation of individual cancer cells. This approach should be useful for more refined surgical staging,
planning, and resection with curative intent.
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Introduction
The incidence of pancreatic ductal adenocarcinoma (PDAC) has in-
creased during the past several decades and now ranks as the fourth
leading cause of cancer death in the United States. Patients usually
present late in the disease process with symptoms of weight loss, pain,
and/or jaundice. While improvements in imaging technology have
generally increased the spatial resolution of scans as well as inter-
ventional capabilities, these technologies rarely allow detection of the
small lesions without anatomic abnormalities or precursor lesions
(pancreatic intraepithelial neoplasia). 18F-fluorodeoxyglucose-positron
emission tomography imaging is generally considered less sensitive
since many cancers do not show increased glucose uptake [1,2] or
are simply too small, i.e., below the detection threshold. As a result,
patients often present with advanced stage disease when the decision
to surgically resect is not straightforward. Moreover, the incidence
of recurrent disease following surgical resection remains high, which
underscores the need for improved detection of residual disease.
Unfortunately, there are currently no reliable intraoperative imaging
approaches to delineate microscopically invading cancers or to dis-
tinguish malignancy from inflammation for more accurate mapping
and detection of cancer spread. In short, there is an urgent need for
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molecularly targeted imaging agents to improve the detection of this
highly lethal disease.
Cathepsin E (CTSE) has emerged as a promising PDAC target from
different lines of research. The Hanahan group demonstrated over-
expression of CTSE in the ripTag model and subsequently confirmed
high levels in the K-ras mouse model. Here, it was shown that 3.5%
of the total protein within PDAC lysates consisted of CTSE protein
(unpublished). Second, a meta-analysis by the Ramaswamy laboratory,
employing whole-genome transcriptional arrays to analyze more than
500 samples (including primary human tumors, cell line screens, mouse
model analysis, and metasearch), identified CTSE as a prime target.
Finally, there are literature reports pointing to CTSE as a target both
recently [3–6] and even dating back to the early 1990s [7–11]. There
are several features that make CTSE a unique imaging target: 1) it exists
only intracellularly and is not secreted, 2) it exists in a pro-form and is
not proteolytically active (thus is not efficiently targeted by activity-
based probes or substrates except for perhaps a small fraction of active
enzyme), and 3) enzyme activity in live cells is not inhibitable by classic
pan-cathepsin inhibitors. Furthermore, unlike other cathepsins (B, D,
S, K) that can show high stromal levels [12–16], CTSE overexpression
appears to be unique to PDAC tissue. Additionally, CTSE is expressed
in the earliest forms of pancreatic intraepithelial neoplasia [3,6]. In-
terestingly, the United States Food and Drug Administration (FDA)-
approved human immunodeficiency virus (HIV) protease inhibitor
ritonavir (RIT; Figure 1B) has been shown to have a reasonable co-
affinity for CTSE [17]. We hypothesized that this small molecule drug
scaffold could be modified to yield high affinity imaging agents for
intraoperative optical imaging and with appropriate pharmacokinetics
for in vivo use.
In this research, we systemically analyzed different RIT variants
and conjugation points, linkers to modulate hydrophilicity, imaging
reporters, and labeling strategies. These compounds were screened
against CTSE protein using surface plasmon resonance (SPR) analy-
sis. We discovered that one particular compound [RIT–tetramethyl-
BODIPY (TMB)] had low nM affinity, was cell permeable, and
was fluorescent. Here, we show that this compound is selective for
PDAC in human tissue samples and allows in vivo imaging of PDAC
in mouse models.
Figure 1. RIT-TMB synthesis and characterization. (A) Synthesis of RIT-TMB (3). (B) Chemical structure of RIT, P2′ thiazole on the right
side of the molecule. (C) HPLC chromatogram and LC-MS analysis of purified RIT-TMB. (D) Binding affinity data for RIT parent compound
and RIT-TMB against human CTSE.
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Materials and Methods
General
RIT was purchased from Selleck Chemicals (Houston, TX), (S )-
N -((2S ,4S ,5S )-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl)-2-(3-((2-
isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamide
(desthiazolylmethyloxycarbonyl, 1) and 2S,3S,5S-5-amino-2-[N -[[(5-
thiozolyl)methoxy]carbonyl]amino]-1,6-diphenyl-3-hydroxyhexane, 4,
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and
BODIPY 493/503 succinimidyl ester (TMB-NHS) was purchased
from Invitrogen (Grand Island, NY). Proton and carbon nuclear mag-
netic resonance (1H and 13C NMR) spectra were recorded on a Varian
AS-400 (400 MHz) spectrometer. Chemical shifts are reported in parts
per million downfield from tetramethylsilane. Data are reported as
follows: chemical shift (δ), integration, multiplicity (bs, broad singlet;
s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), and coupling
constants in Hz. Liquid chromatography-electrospray ionization-
mass spectrometry (LC-ESI-MS) analysis and high-performance liquid
chromatography (HPLC) purifications were performed on a Waters
(Milford, MA) LC-MS System. For LC-ESI-MS analyses, a Waters
XTerra C18 5-μm column was used. Preparative HPLC runs for syn-
thetic intermediates used an Atlantis Prep T3 OBD 5-μM column
[eluents: 0.1% trifluoroacetic acid (TFA) (vol/vol) in water and MeCN;
gradient: 0 to 1.5minutes, 5% to 100%B; 1.5 to 2.0minutes, 100%B].
Nu/Nu mice [Cox-7; Massachusetts General Hospital (MGH), Boston,
MA] were housed and handled according to MGH Institutional Animal
Care and Use Committee guidelines. Mice undergoing surgical pro-
cedures or imaging were anesthetized by isoflurane inhalation at a
flow rate of 2% isoflurane and 2 L/min oxygen, which was reduced to
1 L/min oxygen for extended anesthesia during imaging.Mice implanted
with cells in window chambers and orthotopically in the pancreas were
administered antibiotics in their drinking water. Anesthetized mice were
monitored at all times.
Homology Modeling and Docking Simulations
A homology model of CTSE was obtained as previously described
[18] using the SWISS-MODEL Workspace server (SWISS-MODEL
Workspace, http://swissmodel.expasy.org) [19]. The model was tem-
plated on a crystal structure of pepsin (PEP4). RIT and RIT-TMBwere
docked into the resulting CTSE homology model. Autodock Vina
version 1.1.2 [20] was used for all docking simulations after prepar-
ing files using Autodock Tools 1.5.6rc3 [21]. All bonds were treated
as rotatable with the exception of amide and ring bonds. Docking
simulations were conducted to generate 20 structures at an exhaustive-
ness of 25.
RIT-NH-Ac (5) and Ac-NH-RIT (6) Synthesis
and Characterization
(S)-N -((2S,4S ,5S)-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl)-2-(3-
((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamide,
1 (10 mg, 0.017 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide) (50 mg, 0.261 mmol), triethylamine (600 μl, 4.32 mmol),
and glacial acetic acid (50 μl, 0.870 mmol) were combined in dichloro-
methane (2 ml) and stirred at room temperature for 1 hour. Solvent
was removed under reduced pressure and the resulting crude mixture
was redissolved in 400 μl of acetonitrile water (1:4). The desired (S)-N -
((2S ,4S ,5S)-5-acetamido-4-hydroxy-1,6-diphenylhexan-2-yl)-2-(3-((2-
isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamide
(RIT-NH-Ac, 5) was isolated by HPLC purification in 34.1% yield
and 99% purity; 1H NMR (400 MHz, DMSO-d6) δ 7.65 (d, J =
8.5 Hz, 1H), 7.48 − 7.41 (m, 1H), 7.26 − 7.03 (m, 11H), 5.99 (d,
J = 8.6 Hz, 1H), 4.50 − 4.34 (m, 2H), 4.09 (d, J = 7.2 Hz, 1H),
3.97 (q, J = 9.1, 8.6 Hz, 1H), 3.94 − 3.86 (m, 1H), 3.61 − 3.53 (m,
1H), 3.22 (p, J = 6.9 Hz, 1H), 2.90 − 2.81 (m, 3H), 2.74 − 2.53 (m,
4H), 1.90 − 1.80 (m, 1H), 1.66 (s, 3H), 1.39 (d, J = 8.2 Hz, 2H), 1.28
(d, J = 6.9Hz, 6H), 0.72 (d, J = 6.7Hz, 6H). 2S ,3S ,5S-5-amino-2-[N -
[[(5-thiozolyl)methoxy]carbonyl]amino]-1,6-diphenyl-3-hydroxyhex-
ane, 4 (10 mg, 0.024 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide) (65 mg, 0.339 mmol), triethylamine (790 μl, 5.68 mmol),
and glacial acetic acid (65 μl, 1.14 mmol) were combined in dichloro-
methane (2 ml) and stirred at room temperature for 1 hour. Solvent
was removed under reduced pressure and the resulting crude mixture
was redissolved in 400 μl of acetonitrile water (1:4). 2S ,3S ,5S -5-
acetamido-2-[N -[[(5-thiozolyl)methoxy]carbonyl]amino]-1,6-diphenyl-
3-hydroxyhexane, 6, was isolated by HPLC purification in 30.9% yield
and 99% purity; 1H NMR (400 MHz, DMSO-d6) δ
1H NMR
(400 MHz, DMSO-d6) δ 9.04 (d, J = 0.8 Hz, 1H), 7.85 (q, J =
0.8 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.24 − 7.06 (m, 12H), 6.87
(d, J = 9.3 Hz, 1H), 5.20 − 5.09 (m, 2H), 4.14 − 4.05 (m, 1H),
3.86 − 3.77 (m, 1H), 3.51 (td, J = 6.9, 2.0 Hz, 1H), 2.74 − 2.59 (m,
4H), 1.63 (s, 3H), 1.42 (m, 2H).
RIT-TMB (3) Synthesis and Characterization
(S)-N -((2S,4S,5S)-5-Amino-4-hydroxy-1,6-diphenylhexan-2-yl)-2-(3-
((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamide,
1 (6.9 mg, 0.012 mmol) and BODIPY 493/503 succinimidyl ester,
2 (2 mg, 0.012 mmol) were added to a 2-ml vial. To the same vial, dry
acetonitrile (1 ml) and diisopropylethyl amine (6.3 μl, 0.036 mmol,
3 eq) were added. The reaction mixture was stirred for 14 hours at
room temperature and was purified by preparative HPLC (20 ml/min,
10 minutes, 5% acetonitrile in water to 95% acetonitrile in water;
see specifics above). The fractions were collected and the solvent was
removed by rotary evaporation to yield 11.1 mg of orange solid (63%
yield) in 99% purity; 1H NMR (400 MHz, methanol-d4) δ 8.27 (bs,
1H), 7.84 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 9.4 Hz, 1H), 7.24 (d, J =
4.4 Hz, 4H), 7.19 − 7.12 (m, 6H), 7.07 (ddt, J = 5.4, 4.3, 3.6 Hz, 1H),
6.17 − 6.09 (m, 3H), 4.59 − 4.41 (m, 2H), 4.35 − 4.22 (m, 2H), 4.00 −
3.89 (m, 1H), 3.74 (td, J = 6.9, 1.9 Hz, 1H), 3.36 − 3.20 (m, 1H),
3.21 − 2.93 (m, 5H), 2.89 − 2.62 (m, 4H), 2.43 (s, 6H), 2.40 − 2.25
(m, 2H), 1.94 (dq, J = 13.7, 7.0 Hz, 1H), 1.69 − 1.53 (m, 2H), 1.35
(d, J = 6.9 Hz, 7H), 1.28 (s, 1H), 0.84 (dd, J = 6.7, 4.8 Hz, 11H);
13C NMR (100 MHz, methanol-d4) δ 177.7, 171.6, 170.1, 157.9,
153.7, 153.3, 146.3, 141.5, 139.9, 139.2, 131.0, 129.8, 129.5, 128.5,
128.3, 128.2, 128.0, 126.2, 126.1, 122.1, 114.5, 70.2, 69.2, 60.0, 48.7,
47.4, (39.095), 38.0, 36.5, 34.9, 24.5, 23.3, 23.2, 19.9, 18.7, 16.4,
14.5; LC-ESI-MS m/z (%) ES−: observed, 880.2 [M − H+]−1 (100);
calculated, 880.5 [M − H+]−1.
SPR Measurements
SPR measurements were performed on a Biacore T100 instrument
using a Sensor Chip CM5 (carboxymethylated dextran matrix immo-
bilized on a gold surface). Immobilization reagents (amine coupling
kit) were purchased from GE Healthcare (Pitttsburg, PA). Control
software and data evaluation software supplied with the instrument
were employed for setting up experiments and analyzing data.
Immobilization of CTSE to the sensor surface. Carboxyl groups
on the dextran matrix of flow cell 2 were activated with a 1:1 solution of
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EDC/NHS (600 second injection at 10 μl/min) followed by a solution
of CTSE [20 μg/ml in acetate buffer (pH 4.5), 750 second injection
at 5 μl/min]. The remaining NHS-ester groups on the sensor surface
were quenched with ethanolamine (420-second injection at 10 μl/min).
This resulted in a CTSE immobilization level of 2980 response units.
The reference flow cell 1 (blank immobilization) was prepared by acti-
vating carboxyl groups with a 1:1 solution of EDC/NHS (420-second
injection at 10 μl/min) and quenched with a solution of ethanolamine
(420-second injection at 10 μl/min).
Binding measurements between RIT-NH-Ac/Ac-NH-RIT and
immobilized CTS. Binding was measured at 25°C using sodium
acetate buffer solution (pH 3.5) containing 2% DMSO as running
and dilution buffer. Using the single-cycle kinetics method, the
analyte was injected in duplicate at increasing concentrations from
7.8 to 2000 nM in 1:4 dilution in a single cycle without regeneration.
The resulting binding curves were double reference subtracted and
fitted to a 1:1 Langmuir binding model for analyses.
Biochemical Assays
We used a commercially available assay to determine CTSE inhibi-
tion. In short, recombinant human CTSE (10 μg, 1294-AS; R&D
Systems, Minneapolis, MN) was diluted with 100 μl of 25 mM
MES and 150 mM NaCl (pH 6) buffer. From the resulting solution,
10 μl was added to 990 μl assay buffer (0.1 M NaOAc, 0.1 M NaCl,
pH 3.5). This solution was incubated for 30 minutes at room temper-
ature. It was then added to 4 ml of assay buffer. Separately, the fluoro-
genic peptide substrate (Mca-PLGL-Dpa-AR-NH2, R&D Systems
ES001) was diluted 1:299 in assay buffer. The assay was performed
in a 96-well, black, flat-bottomed plate. To each well, the designated
dilution of RIT-TMB, RIT, RIT-NH-Ac, and Ac-NH-RIT was added.
Control samples did not contain inhibitor and backgroundmeasurement
samples did not contain CTSE. All reaction mixtures were adjusted
to a final volume of 100 μl. To each well, 49.5 μl of CTSE was then
added. The inhibitor was incubated with the CTSE for 3 minutes at
room temperature. Then, 49.5 μl of fluorogenic substrate was added to
each well. The resulting concentrations of the inhibitor ranged from
0.01 nM to 10 μM. All experiments were performed in triplicate. This
mixture was incubated for 7 minutes at room temperature. The fluo-
rescence of each well was measured using a Tecan Safire 2 micro-
plate reader (Tecan Group, Mannedorf, Switzerland). Half maximal
inhibitory concentration (IC50) values were calculated from raw
fluorescence data using Prism (GraphPad Software, La Jolla, CA).
Cell Culture, Cloning, and Generation of Fluorescent
Cell Lines
MIA PaCa-2 (PaCa-2) and PANC-1 human pancreatic adeno-
carcinoma cells (ATCC, Manassas, VA) were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS and 1% glu-
tamine/penicillin/streptomycin (Mediatech, Herndon, VA). AsPC1
(human), Panc02, and AH367 pancreatic carcinoma cell lines were
grown in RPMI supplemented with 10% FBS and 1% glutamine/
penicillin/streptomycin (Mediatech). Panc02 were kindly provided by
Dr Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology
and Biology at the National Cancer Institute. AH367 were kindly
provided by Dr Nabeel Bardeesy at MGH. All cells were grown in a
37°C humidified incubator with 5% CO2. Human CTSE (Human
Mammalian Gene Collection–verified FL cDNA, clone ID 5174814)
in a pSPORT6 vector (Thermo Scientific Open Biosystems, Waltham,
MA) was amplified using the Platinum PCR SuperMix High Fidelity
(Invitrogen/Life Technologies) and gel purified using the Qiaex gel
purification kit (Qiagen, Venlo, The Netherlands), then cloned into
a BamH1/EcoR1-digested pLVX-mCherry-N1 plasmid using the In
Fusion Cloning Kit (Clontech, Mountain View, CA). Ligated DNA was
transformed into TOP10 cells using the manufacturer recommended
rapid transformation protocol (Invitrogen/Life Technologies). Plasmid
DNA was extracted from ampicillin-resistant colonies grown first on
Luria-Bertani agar plates and then in Luria-Bertani broth, and plasmids
were verified with DNA sequencing (Genewiz, South Plainfield, NJ).
Lentiviral particles were generated by transfecting the HEK293T
cell line with packaging vectors (pMDL gag/pol, pRSV Rev, VSV-g;
obtained from Addgene, Cambridge, MA) and pLVX-CTSE-mCherry
for approximately 3 days, at which point the media were collected and
filtered through a 0.45-μm cellulose acetate syringe filter, aliquoted into
cryotubes, and snap frozen in liquid nitrogen. Cells (1 × 105 cells/well)
were seeded in a 12-well plate and transduced with lentivirus in a
1:1 ratio with growth medium with 5 μg/ml polybrene. After 72 hours,
cells were trypsinized and split into dishes with growth medium con-
taining 3 μg/ml puromycin. For imaging experiments, the brightest
cells were sorted using the FACS Aria II (BD Biosciences). Sorting was
performed at the Harvard Stem Cell Institute–Center for Regenerative
Medicine Flow Cytometry Core facility at MGH.
Western Blot
Lysate was collected from cells (AsPC-1, PANC1, PaCa-2,
PANC02, and AH367) grown in 10-cm dishes using 1× RIPA buffer
(Cell Signaling Technology, Danvers, MA) containing protease in-
hibitors (Roche, Indianapolis, IN) and homogenized using a 23-gauge
syringe needle. Protein concentrations were determined using the
microBCA assay (Pierce, Rockford, IL). Tris-glycine 4% to 12%gradient
gels (Invitrogen/Life Technologies) were loaded with equal protein
per well and run at 175 V using the mini-cell apparatus (Invitrogen/
Life Technologies). Proteins were transferred onto polyvinylidene di-
fluoride (PVDF) membrane using the iBlot apparatus (Invitrogen/Life
Technologies). The blots were blocked in SuperBlock buffer (Invitrogen/
Life Technologies) for 1 hour at room temperature, incubated in primary
antibodies against CTSE (C7 clone; Santa Cruz Biotechnology) or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; R&D Systems)
in a 5% milk–TBS–Tween 20 solution overnight at 4°C, then washed
in TBS–Tween 20. Blots were then incubated in secondary antibodies
conjugated to HRP in 5% milk–TBS–Tween 20 solution at room
temperature for 1 hour and then washed in TBS–Tween 20. West Pico
chemiluminescent substrate (Pierce) was applied to the membranes for
5 minutes, at which point blots were exposed to film (Eastman Kodak)
and developed.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Lysate was collected from cells grown in 10-cm dishes using RLT
buffer from the RNeasy extraction kit (Qiagen) and homogenized using
a 23-gauge syringe needle. RNA was extracted using the manufacturer’s
recommended protocol, including the optional DNAse step. Quantita-
tive reverse transcription–polymerase chain reaction was carried out
using the TaqMan RNA-to-CT One-Step Kit and TaqMan Gene Ex-
pression Assays for human CTSE and GAPDH (Applied Biosystems/
Life Technologies), with the ABI7500 Fast Thermal Cycler. Relative
expression was determined using the 2−ΔΔCt method, with PaCa-2
parent as the calibrator.
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Dose-Response Assays
CTSE-mCherry cells (1 × 105 cells/well) were seeded into 48-well
black-wall, clear-bottom plates (Corning) and incubated for 24 hours
before adding different concentrations of RIT-TMB. After incubating
for 15 minutes at 37°C, cells were washed three times with phosphate-
buffered saline (PBS) and the fluorescence levels were measured with
a SynergyMx plate reader (Biotek, Winooski, VT) with excitation
at 503 and 587 nm and emission at 510 and 610 nm for TMB
and mCherry, respectively. Following fluorescence measurement, pro-
teins were extracted using RIPA lysis buffers and quantified using BCA
assay (Pierce).
Blocking Experiments
CTSE-mCherry cells (1 × 105 cells/well) were seeded into 48-well
black-wall, clear-bottom plates (Corning) and incubated for 24 hours
before incubation either with RIT (50 μM) for 30 minutes at 37°C
and subsequently RIT-TMB (10 nM) for 15 minutes at 37°C or
with just RIT-TMB (10 nM) for 15 minutes at 37°C. Following the
incubation, cells were washed three times with PBS and the fluorescence
levels were measured with a SynergyMx plate reader (Biotek) with ex-
citation at 503 and 587 nm and emission at 510 and 610 nm for
TMB and mCherry, respectively. Following fluorescence measurement,
proteins were extracted using RIPA lysis buffers and quantified using
BCA assay (Pierce).
Immunohistochemistry and Co-staining
To detect CTSE expression in PDAC tumor tissue, paraffin-
embedded human tissue sections (tissue microarray) were deparaffi-
nized and rehydrated before antigen retrieval procedure. Heat-induced
epitope retrieval was performed using retrieval solution (pH 6.0; BD
Biosciences) according to the manufacturer’s protocol. The tissue
sections were incubated in 1% hydrogen peroxide solution to block
endogenous peroxidase activity and blocked with 4% normal rabbit
serum in PBS. The sections were stained with goat anti-human CTSE
antibody (R&D Systems), followed by biotinylated anti-goat IgG
(Vector Laboratories, Inc, Burlingame, CA). For paraffin-embedded
mouse tissue, goat anti-mouse CTSE antibody (R&D Systems) was
used. Vectastain ABC Kit (Vector Laboratories, Inc) and a 3-amino-9-
ethylcarbazole substrate (Dako, Carpinteria, CA) were used for color
development, and all sections were counterstained with Harris hema-
toxylin solution (Sigma-Aldrich, St Louis, MO). The images of slides
were captured and digitized automatically at a magnification of ×40
(NanoZoomer 2.0RS; Hamamatsu, Hamamatsu City, Japan).
Human biopsy samples, obtained through an Institutional Review
Board (IRB)-approved protocol, were used to section 5-μm-thick frozen
sections. The frozen sections were briefly fixed and CTSE staining was
performed by applying goat anti-humanCTSE antibody (R&DSystems)
and biotinylated anti-goat IgG (Vector Laboratories, Inc). The sections
were incubated with streptavidin Alexa Fluor 594 (Invitrogen) to detect
CTSE expression in tissue. After washing the slides with PBS, 20 μM
RIT-TMBwas incubated at room temperature for 1 hour and the images
were captured using BX63 (Olympus, Center Valley, PA) equipped with
Neo sCMOS (ANDOR Technology, South Windsor, CT)—TXRED:
EX562/40, EM624/40, DM593 for CTSE and green fluorescent
protein (GFP): EX472/30, EM520/35, DM495 for RIT-TMB.
Immunofluorescence Staining and Microscopy
PaCa-2 CTSE-mCherry cells were seeded in eight-well chamber
slides coated with gelatin and grown overnight at 37°C and 5%
CO2. Fixed with 4% paraformaldehyde in PBS, the cells were per-
meabilized with 0.1% Triton X-100/1% BSA in PBS for 30 minutes.
Cells were incubated with anti-CTSE monoclonal antibody (1:50;
Santa Cruz Biotechnology) for 1 hour at room temperature, then
washed three times with PBS/0.1% Triton X-100. The cells were
then stained with an IgG-Cy5 secondary antibody (1:100; Millipore,
Billerica, MA) for 30 minutes at room temperature and washed three
times with 0.1% Triton X-100/PBS. Finally, cells were stained with
RIT-TMB in DMSO for 30 minutes, washed three times with PBS,
stained with Hoechst dye for 10 minutes, and washed three times with
PBS. Prolong gold reagent was added to each of the wells, and a
coverslip was mounted over the slide. Images were acquired using an
Olympus 80i microscope.
In Vitro Live Cell Imaging
Both parent and CTSE-mCherry cell lines (PaCa-2, PANC-1,
AsPC1, Panc02, AH367) were seeded in ibidi coat 96-well plates
(ibidi, Verona, WI) and allowed to attach overnight. The cells were
incubated at 37°C with varying concentrations of RIT-TMB or
TMB alone in DMSO for 20 minutes, at which point the cells were
washed with PBS and put into phenol red–free growth medium. Live
cell microscopy was carried out using a DeltaVision imaging system
(Applied Precision, Issaquah, WA), consisting of an environmental
chamber heated to 37°C, with CO2 bubbled through a water bath,
an automated Olympus IX70 inverted microscope, and a CoolSNAP
HQ2 CCD camera.
Pharmacokinetics Experiments
Blood half-life of RIT-TMB was quantified by intravital microscopy
imaging of vessels in the ear of Nu/Nu control mice. AngioSenseR 680
(PerkinElmer, Waltham, MA) was injected intravenously into the
tail vein with a catheter to allow focusing on the vessels in the ear. A
40-minute time-lapse imaging series with 10-second interval was ini-
tiated in the fluorescein isothiocyanate and 680 channel before injec-
tion of RIT-TMB [7.5 μl of 10 mM RIT-TMB in DMSO (75 nmol)
diluted with 17.5 μl of dimethylacetamide/Solutol (1:1), then diluted
with 10 × 17.5 μl of 0.9% saline] into the tail vein. Average fluores-
cence intensity of three ROIs within vessels minus average background
of three regions of interest (ROIs) of images collected before injection of
probe was plotted against the time after probe injection using Prism
5.0a (GraphPad Software).
Intravital Imaging
Titanium dorsal skin fold chambers (APJ Trading Co, Inc, Ventura,
CA) were surgically implanted in the dorsal skin fold of Nu/Nu mice.
PaCa-2 CTSE-mCherry tumor cells (5 × 106/injection) mixed 1:1 with
Matrigel (Becton Dickinson) were injected into the window chamber
subcutaneously and grown for approximately 1 week, at which point
the skin within the window was removed and replaced with a 10-mm
diameter glass coverslip that was secured with a C-clip. On the day of
imaging, the window chambers of anesthetized mice were immobilized
using a custom-made holder seated on a 37°C heating pad. RIT-TMB
[7.5 μl of 10 mM RIT-TMB in DMSO (75 nmol) diluted with 17.5 μl
of dimethylacetamide/Solutol (1:1), then diluted with 10 × 17.5 μl 0.9%
saline] was injected intravenously into the tail vein. The window
chambers were imaged for at least 2 hours following injection to moni-
tor accumulation of the probe in tumor cells. Static and time-lapse
images were collected using a customized Olympus FV1000 based
on a BX61-WI confocal microscope. The objectives used were
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2/340 XLFluor (NA 1/4 0.14, air), 20 UPlanFL (NA 1/4 0.50, water),
and 60 LUMFL N (NA 1/4 1.10, water). TMB and mCherry were
excited using the 488-nm line of an argon ion laser and a 559-nm diode
laser, respectively. Emitted light was separated using a 405/488/559/
635-nm dichroic beam splitter and refined using the band-pass filters
BA505-540 and BA575-605.
Orthotopic Tumor In Vivo Imaging
Orthotopic tumors were prepared by first locating and sterilizing
the skin over the spleen (∼5 mm below the rib cage). An incision
(1 cm) starting at the apex of the spleen was made through the
abdominal skin and muscle allowing visualization of the pancreas.
The pancreas was externalized using a damp cotton swab and PaCa-2
CTSE-mCherry tumor cells (5 × 105/injection) mixed 1:1 with Matrigel
(Becton Dickinson) were injected into the exposed pancreatic lobe.
The pancreas was positioned back into the abdominal cavity and the
incision closed with 5-0 suture. Following surgery, mice were adminis-
tered a nonfluorescent diet until day of imaging. Images were collected
with an intravital laser scanning microscope as described above. A
custom-made tissue stabilizer [22] was used to reduce motion artifacts
induced by breathing and cardiac activity and to stabilize the imaging
focal plane. Samples were excited at 488 nm with an air-cooled argon
laser (Melles Griot, Carlsbad, CA) for visualization of the RIT-TMB.
Results
Design of RIT-TMB was guided by binding assays of two truncated
derivatives of the HIV protease inhibitor RIT, RIT-NH-Ac, 5, and
Ac-NH-RIT, 6, as well as docking simulations of RIT (Autodock Tools
Figure 2. PDAC cell line characterization. (A) Dose-response curve of RIT-TMB in PaCa-2 CTSE-mCherry cells. (B) Competitive inhibition
of RIT-TMB with RIT in PaCa-2 CTSE-mCherry cells.
Figure 3. In vitro live cell microscopy imaging of RIT-TMB in PaCa-2 and PaCa-2 CTSE-mCherry. (A) PaCa-2 cell line: anti-CTSE Cy5 mAb
(red), RIT-TMB (green). (B) Single PaCa-2 CTSE-mCherry cell: CTSE-mCherry (red), RIT-TMB (green), Hoechst nuclear stain (blue).
Neoplasia Vol. 15, No. 7, 2013 Targeting Cathepsin E in Pancreatic Cancer Keliher et al. 689
Figure 4. In vivo dorsal window chamber intravital microscopy. In vivo imaging, 1 hour post injection, of RIT-TMB, PaCa-2 CTSE-mCherry
cells in dorsal window chamber.
Figure 5. In vivo PDAC orthotopic intravital microscopy. (A) Setup of intravital window chamber imaging. (B) Blood half-life as measured
by serial fluorescence imaging. (C) Representative section showing CTSE-mCherry expressing PDAC cells. (D) Identical section as
shown in C, following intravenous administration of RIT-TMB. Some of the agent can still be seen in large vessels (bottom right). Note
the good co-localization with CTSE-mCherry.
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1.5.6rc3 [21] and Autodock Vina [20]) with a previously described
homology model (SWISS-MODEL Workspace, http://swissmodel.
expasy.org) [19] of the mature CTSE structure. Competitive binding
assay of RIT-NH-Ac and Ac-NH-RIT against recombinant CTSE
(Figure W1C ) demonstrated that RIT-NH-Ac has a 30-fold higher
affinity over Ac-NH-RIT. This was supported by SPR binding assays
(Figure W1D). RIT-NH-Ac was found to have a low nanomolar
affinity for CTSE (41 nM), while no SPR binding was observed for
Ac-NH-RIT. Docking simulations of the parent RIT compound
demonstrated the P2′ region of the molecule extended out from the
binding pocket of the CTSE homology model (Figure W2). We there-
fore designed imaging agents based on modification at this position.
Synthesis of RIT-TMB (Figure 1A) was achieved from the commercial
reagents, desthiazolylmethyloxycarbonyl ((S)-N -((2S ,4S ,5S)-5-amino-
4-hydroxy-1,6-diphenylhexan-2-yl)-2-(3-((2-isopropylthiazol-4-yl)
methyl)-3-methylureido)-3-methylbutanamide), 1, and amine reactive
tetramethyl BODIPY NHS ester, 2. After stirring for 14 hours in the
presence of base and subsequent HPLC purification, RIT-TMB, 3,
was isolated in 63% yield and 99% purity (Figure 1C ). The identity
of RIT-TMB was confirmed by HPLC-LC/MS (Figure 1C), 1H-NMR,
and 13C-NMR.
The inhibitory strength of RIT-TMB was tested against human
recombinant CTSE (results shown in Figure 1D) and compared to that
of the parent molecule RIT. RIT-TMB was found to have an IC50 of
39.9 ± 1.2 nM, while RIT had an IC50 of 5.5 ± 1.3 nM (similar to
previous reports [17]), demonstrating that conjugation of RIT and
tetramethyl BODIPY fluorochrome was tolerated by the enzyme.
We initially examined the native protein and mRNA expression levels
of a series of mouse and human pancreatic cancer cell lines that showed
MIA PaCa-2 (PaCa-2) cells as having moderate amounts of protein
(Figure W5). To visualize CTSE in co-localization studies, we gener-
ated PaCa-2 cells that express a CTSE/mCherry fusion protein. Experi-
ments were then conducted to determine cell permeability of the probe
and theminimal concentration required for imaging (Figure 2A). PaCa-2
CTSE-mCherry cells were plated and treated with serial dilutions of
RIT-TMB. Following 15-minute incubation at 37°C and washes, we
found that probe uptake was rapid (completion within 5–10 minutes).
Preincubation of PaCa-2 CTSE-mCherry cells with RIT resulted in a
substantial reduction in cellular uptake of RIT-TMB (73.5% reduction
in signal; Figure 2B), while incubation with TMB not conjugated to the
truncated RIT resulted in no cellular uptake (Figure W4). Probe uptake
in treated and untreated wells was normalized against the fluorescence
signal from the PaCa-2 CTSE-mCherry signal.
Co-localization of RIT-TMBwith CTSE was tested in various PDAC
cell lines using an anti-CTSE Cy5 monoclonal antibody. RIT-TMB
demonstrated exceptional co-localization with anti-CTSE mAb and
mCherry fluorescence in native and transfected PaCa2 lines (Pearson
coefficients of 0.9544 and 0.9816, respectively; Figure 3).
The blood half-life was determined by serial imaging and fitted to a
two-compartment decay model where the weighted half-life was found
to be 1.4 minutes (Figure 5B). We tested RIT-TMB in two in vivo
models of PDAC to evaluate its performance. The first in vivo PDAC
model, a dorsal window chamber model [23], was prepared with the
PaCa-2 CTSE-mCherry cell line. After allowing a 7-day cell expansion
period, time-lapse imaging experiments of RIT-TMB were performed
for 2 hours post-injection to monitor accumulation of the probe in
tumor cells. Figure 4 shows representative examples that confirm
in vivo cellular uptake of RIT-TMB with good co-localization.
Figure 6. Histology of human biopsy samples. (A) Human tissue tumor microarray. (B) Human PDAC metathesis in the liver (fine needle
aspirate). (C) Anti-CTSE immunohistochemistry (adjacent slice as D and E). (D) Anti-CTSE immunofluorescence. (E) RIT-TMB staining,
same slice as D (20 μM RIT-TMB for 1 hour).
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RIT-TMB was also tested in a second in vivo model, an orthotopic
injection of PaCa-2 CTSE-mCherry cells into the pancreas. PaCa-2
CTSE-mCherry cells were injected into the pancreas and expanded
for 7 days. On the day of imaging, mice were anesthetized and the pan-
creas subsequently exposed. Before injection, no signal was observed
at 488-nm excitation and 522-nm emission. After intravenous RIT-
TMB injection, accumulation of RIT-TMB within the tumor was ob-
served by monitoring 488/522 nm (Figure 5, C and D) with good
co-localization with CTSE-mCherry signal of the PaCa-2–transfected
cancer cells.
We finally tested RIT-TMB by immunofluorescence in murine and
human biopsy specimens. Tumor tissue sections excised from 10-week-
old KRAS p53−/− PDAC mice demonstrated good co-localization
between double staining with anti-CTSE immunofluorescence and
RIT-TMB (Figure W2) with particularly high accumulation within
the pancreatic ducts. Human immunohistologic staining demonstrated
consistent positive CTSE staining in 13 of 14 microarray samples
analyzed (Figure 6B). Finally, RIT-TMB demonstrated good co-
localization with the anti-human CTSE antibody (Figure 6, C–E )
when tested in fresh human biopsy samples.
Discussion
There are currently no clinically approved real-time imaging methods
that can effectively detect invasive pancreatic cancer cells or discrimi-
nate cancer cells from adjacent noncancerous cells during surgery.
While surgical removal of localized PDAC remains the clinical gold
standard, teasing out what is cancer and what is surrounding inflam-
mation remains highly challenging due to diffuse tumor infiltration,
microscopic disease, and complex anatomy. The availability of an
intraoperative imaging agent with high affinity for PDAC at the
whole body and cellular levels would be an invaluable addition to
our current surgical and research armamentarium.
Here, we show the synthesis and characterization of a non-peptide
small molecule dual function inhibitor and imaging agent of CTSE
based on an FDA-approved protease inhibitor. This was achieved in
a single synthetic step with high chemical purity from commercial
starting materials. Chemical modification of the parent compound,
RIT, was shown to result in a CTSE affinity in the tens of nano-
molar range. We demonstrated excellent in vitro imaging of RIT-
TMB with a transfected mCherry-CTSE protein within a PDAC cell
line (PaCa-2). No signal was observed for the free fluorochrome in
the same cell line thus supporting the targeted nature of the probe.
More significantly, rapid co-localization was observed in two in vivo
models of PDAC.
In addition to PDAC, CTSE overexpression has been described
in gastric carcinomas [11], cervical adenocarcinoma [24], and adeno-
carcinoma of the lung [25]. Molecularly targeted imaging agents such
as RIT-TMB could be used to explore the biology of CTSE in these
cancers as well as monitor response to targeted therapies. Similar to
other targeted low-affinity reagents with pancreatic cell specificity
[26], it is expected that these approaches could be useful not only
during surgery but also in endoscopy, interventional procedures, and
whole-body imaging.
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Figure W1. Synthesis and characterization of RIT-NH-Ac (5) and Ac-NH-RIT (6). (A) Synthetic schemes of 5 and 6. (B) LC-MS analyses of
purified of 5 and 6. (C) Binding affinity data for 5 and 6 against human CTSE. (D) SPR binding data for the interaction of 5 with immobilized
CTSE. Red and blue curves depict experimental data (two separate runs); best-fit models overlaid in black.
Figure W2.Modeling. Simulated docking of RIT (A) and RIT-TMB (B)
with homology model of CTSE.
Figure W3. Immunofluorescent anti–CTSE/RIT-TMB double stain-
ing of tumor section excised from 10-week-old KRAS p53−/−
model. (A) RIT-TMB (20 μM RIT-TMB for 1 hour). (B) Anti-CTSE
immunofluorescence.
Figure W4. PaCa-2 CTSE-mCherry cells incubated with RIT-TMB and TMB (fluorochrome only). CTSE-mCherry (red), RIT-TMB and
TMB (green), and 4′,6-diamidino-2-phenylindole (blue).
Figure W5. Relative quantification of CTSE protein and mRNA
expression in PDAC cell lines.
